Is Platelet Adhesion Assay Able To Quantify Drug-Induced Platelet Dysfunction?

ABSTRACT

The platelet adhesion assay (PADA) is an innovative method for the detection of both normal, pathologically increased or decreased platelet adhesiveness. Adhesion is the first important phase of platelet activation, followed by shape change and aggregation. Adhesion is triggered by glycoproteins (GP) on the platelet surface, mainly by GPIIb/IIIa, and to a lesser extent also by GPIb/V/IX. Since fibrinogen serves as adhesive protein for GPIIb/IIIa receptors, and since the PADA uses polymer particles that become coated with fibrinogen, the PADA is able to monitor GPIIb/IIIa receptor antagonists and to detect overdosing, potentially leading to bleeding complications. Ex vivo, citrated whole blood from healthy volunteers and patients was spiked with increasing GPIIb/IIIa inhibitor concentrations and PADA was measured. Comparing these results with GPIIb/IIIa receptor occupancy, determined by FACS, a basic consistency of the data was shown. Via intracellular signaling, the adenosine diphosphate (ADP) receptor mechanism is closely involved in the activation of GPIIb/IIIa receptors so that also ADP receptor antagonists of the thienopyridine type, especially clopidogrel, can be quantitatively determined by the PADA. In patients under clopidogrel therapy, the therapeutic effect was monitored and also individual dose adjustments were realized. Furthermore, patients having partial or full clopidogrel resistance were identified. Overdoses can be detected as well.

KEYWORDS

Platelets - adhesion - monitoring - antiplatelet medications

REFERENCES

• 1 Li C K, Hoffmann T J, Hsieh P Y, Malik S, Watson W C. The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury.  Thromb Res. 1998;  92 S66-S77
• 2 Lakkis N M, George S, Thomas E, Ali M, Guyer K, Carville D. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.  Catheter Cardiovasc Interv. 2001;  53 346-351
• 3 Madan M, Berkowitz S D, Christie D J et al.. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.  Am Heart J. 2001;  141 226-233
• 4 Smith J W, Steinhubl S R, Lincoff M et al.. Rapid platelet-function assay: an automated and quantitative cartridge-based method.  Circulation. 1999;  99 620-625
• 5 Varon D, Lashevski I, Brenner B et al.. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions.  Am Heart J. 1998;  135 S187-S193
• 6 PFA-100® System .Product information (CD-ROM). When You Need To Assess Platelet Function Dade Behring Marburg, Germany; 2001
• 7 Varon D, Dardik R, Shenkman B et al.. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions.  Thromb Res. 1997;  85 283-294
• 8 Coller B S. Anti-GPIIb/IIIa drugs: current strategies and future directions.  Thromb Haemost. 2001;  86 427-443
• 9 Mukherjee D, Moliterno D J. Monitoring antiplatelet therapy: what is the best method?.  Clin Pharmacokinet. 2000;  39 445-458
• 10 Quinn M, Deering A, Stewart M, Cox  D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.  Circulation. 1999;  99 2231-2238
• 11 Peter K, Kohler B, Straub A. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.  Circulation. 2000;  102 1490-1496
• 12 Plavix® 75 mg .Package insert. Sanofi-Synthelabo. Berlin, Germany; September 2002